Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Share with your joy. But how do you deal with your property in Baltimore while you are away? I want to be mobile too, but feal headace on unmovable things left
Agree with you on JADA, how many reserve years the company have based on current production? What is the proper value of this company based on current jade price?
PRIM vs. KLIC: Which one is more cyclic? It seems to me that KLIC is projected to earn over $0.3 per share this quarter, over 40% earning growth sequentially. Do not understand why KLIC has not been discussed much (except from me) here after blowup earning report lately. But I have no complain as it is quite profitable for me.
Not sure, but RODM's principle transaction loss may be larger this quarter considering market condition now. Thinking to sell some for safe.
Add RODM's $$6.58 million principal transaction loss, it actually earned sinificantly more than what it looked like. Outlook for this quarter is good as well. Just bought some at $4.4
I was the buyer of CMTX shares this morning too
Thanks, Mandjb, here is an interesting graph:
http://finance.yahoo.com/q/bc?t=my&s=MPAA&l=on&z=m&q=l&c=klic
KLIc and MPAA may be like twins. Their time may just come now. I wish that you could make more money on MPAA than I make on KLIC.
Cheers
KLIC vs. MPAA: KLIC may be much better buy than MPAA though both may be undervalued, when you compare their earning, earning growth, balance sheet, near term catalyst. They are in the different fields, but both may be cyclic
KLIC's strength today has pushed my portfolio into strong green for the week after the first weekly loss last week for the year. What I do not understand is why KLIC is still traded below $8, considering it just produced huge cash, earned 0.21 last quarter and will very likely earn over 0.23 per share based on projected revenue this quarter. If this is not a stock to buy, tell me better one.
KLIC 10Q was filed this morning with upbeating outlook. I believe $8 will come soon, considering its earning per share should be over $0.3 based on its projected revenue. If outlook continues to be poisitive after this quarter, $10 share price may be reached.
Here is some part from 10q:
Considering "Though the semiconductor industry's cycle can be independent of the general economy, global economic conditions may have direct impact on demand for semiconductor units and ultimately demand for semiconductor capital equipment and expendable tools. Following dramatic deterioration in the global economy in the first half of our fiscal 2009, business conditions in the semiconductor industry began a recovery that continued through the end of our fiscal 2009. Demand for our core products continued to improve in the beginning of fiscal 2010 and demand is projected to remain strong at least through March 2010. However, our visibility into future demand is generally limited and forecasting is difficult. There can be no assurances regarding levels of demand for our products, and we believe historic industry-wide volatility will persist.
To mitigate possible negative effects of this industry-wide volatility on our financial position, we have de-leveraged and strengthened our balance sheet. During fiscal 2009, we reduced our debt by $88.4, and we completed a public equity offering of 8.0 million common shares which raised $38.7 million of net proceeds. We ended the first quarter of fiscal 2010 with cash and cash equivalents totaling $175.2 million, $30.6 million higher than our fiscal year end. We believe a strong cash position allows us to continue making longer term investments in product development and in cost reduction activities throughout the semiconductor cycle. "
Nelson/Skill, KLIC's revene rose about $18 million last quarter vs. its previous quarter, but its earning rose from 0.08 to 0.21 per share. It projects its revenue will rise another $18 million approximately this quarter, so I guess its earning per share will be about 0.34 per share this quarter. Even if it were at its peak cycle, its share price below $6 is still quite cheap. The fact is that it may be just the beginning of its rising cycle.
Do not understand why KLIC's blow up earning report this morning along with upbeating prejection for this quarter has not moved its share price significantly. Anyway, just bought 4000 KLIC shares at $5.4.
KLIC got great earning report and forecast even better upcoming quarter. The stock is traded at forward pe below 5
NSOMNIYAK CHALLENGE:
AYSI.OB: high growth
CHIO: too cheap
CSSV.OB: value play
CYXN.OB: can not believe why I could get at this price even out of finacial crisis
JADA.OB: high potential
WTN.TO: wait for turnaround
My Powerball: onp
Thanks, cl#1, The only reason why I only exposed a few percentage of my portfolio in gold stock is I feel hard to value these companies. For example, ABR.v has the great news today
http://finance.yahoo.com/q;_ylt=AshunmPlaGKIv7VyEEaZCOCtcq9_;_ylu=X3oDMTB0NWtwaTVmBHBvcwMxBHNlYwNuZXdzYXJzdGFydARzbGsDYWJy?s=abr.v&d=t
but I do not understand how much it means (how much gold in reserve, what's cost, etc). If you could shed some light on this issue with your tight time, I would greatly appreciate.
Wow, amazing! CL#1, you have just posted a message making me laugh most today. Thanks and best wish for this new decade. Just got a little more CYXN at amazing price, as they have just released restounding the 4th quarter result with more growth to come.
Wade & Tim, What is your annual COMPOUNDED return during said period? It is very interesting to know, as average annual return could be quite misleading. For example, a friend of mine has average annual return about 99% in the past 7 years but annual compounded return merely 57% during the same period. Thanks in advance.
Thanks, Traderfan on CYXN, Even if all prefered is converted into common shares, it still earned about $0.06 per share during the 4th quarter of this year. Considering its high growth, anything below $2 is extremely undervalued. It was traded over $2 two years ago When it earned much less. The company transferred its business from wholesale to retail, which is the reason why it had some revenue/earning disruption during the first 3 quarters of this year and why its share price drop so much. Now transition period is behind.
CYXN: Agree with you. Considering high growth potential from government policy and population dynamics, I would think it may rise over $4 within one year
cyxn, a potential 10-bag: prejected to earn $0.1 per share during the 4th quarter, only traded at $0.47
China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China Yongxin Pharmaceuticals" or the "Company"), a leading manufacturer, distributor and retailer of Chinese traditional medicines, pharmaceutical products, natural health products, health food, cosmetics, and medical equipment in Northeastern China, today announced its projected financial results for the year ending December 31, 2009.
Revenues for the full-year 2009 are projected to be $46.1 million, a 22% decrease from $59.1 million for 2008. The decrease in total revenue is due to the transition of the Company's sales strategy, which, because of the uncertain direction of the National Medical Policy, has been refocused from the wholesale sector to the retail and medical facilities sector. While a broader product portfolio and expanded marketing activities increased 2009 revenues from the Company's retail drug stores by approximately 30% over the prior year, it was not sufficient to completely offset the decrease in the Company's wholesale business, resulting in comparably lower total net revenue.
For 2009, net income is projected to be approximately $5.4 million, a 35% increase over the $4.1 million for 2008. The increase primarily is related to higher margin retail and medical facilities sales.
The Company expects to report that diluted earnings per share increased to $0.16 for 2009 compared to $0.13 for 2008, based on 34.4 million and 31.2 million shares respectively. Provision for income tax in 2009 is $2.7 million compared to $1 million in 2008.
Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin, commented that during 2009, the Company's wholesale business was impacted by customers waiting for specifics on the new healthcare reform plan. "However, on August 18th, the Chinese government issued China's Essential Drug List (EDL) which included over 300 commonly used pharmaceuticals that will be subsidized by the government to provide easier access to all citizens. We are pleased that China Yongxin is a retailer or distributor of 295 of the products on that list. We are further encouraged by the increasing momentum toward healthcare reform and the government's efforts to boost domestic spending. During 2009, we also added 12 high margin pharmaceutical products with exclusive distribution rights in Jilin province and we expect this to drive market share gains and growth during the coming year," Mr. Liu said.
Thanks, but only got 5000 CSSV shares and hope more can be filled. My calculation is that it earned about 0.1 per share fully diluted during the 4th quarter
CTS.v, revenue rising over 300% for the second quarter in a row, earning $0.009 per share last quarter, rising backlog, traded at merely $0.31. Here is the earning press release this morning:
http://finance.yahoo.com/news/Cantronics-Revenue-Up-353-in-ccn-2269305.html?x=0&.v=1
Here is the new contract win whose revenue will be recognized this quarter:
http://finance.yahoo.com/news/Cantronic-Systems-Inc-ccn-3234374678.html?x=0&.v=1
http://finance.yahoo.com/news/Cantronic-Systems-Inc-iw-3466308831.html?x=0&.v=1
Dow 11000 Oil 80 Gold 800
Thanks, just sold my MRM at $15.95, a true precious Christmas present.
AYSI: add unfavourable foreign exhange, it would have earned 0.035 per share. If add half of new mill starting cost, then It would have earned 0.065 per share.
No surprising the share price drop at the beginning, then begin to recover.
Thanks, Researcher, and congratulation that you are the real champion!
Count me and I will hold this until $20
timhyma, trading does help investment return, as my actual portfolio trading regularly has risen nearly 300% year to today instead of nearly 180% in the contest.
Nsomniyak Challenge:
ALRC.OB: Deeply undervalued with good earning growth
AYSI.OB: wait for turn around great news
CPBY: Good balance sheet along with high growth
CSKI: Nasdaq listed company with pe below 5, unbelievable
HNU.TO: natuaral gas price can not go any lower
YHGG.PK: It will be listed in OTC or major stock exchange shortly
Thanks. Did you buy some OPAI.ob last Feb?
Thanks for your kind words. I guess I am just lucky.
Valuemind
Congratulations on leading at the halfway point.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39265893
Len
PDLI has great guidance with forward pe about 5, and should have some excitement today
NCLIu VILLAGE, Nev., June 8 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI - News) today announced revenue guidance for the second quarter ended June 30, 2009 of approximately $125 million, as compared with $106 million for the second quarter of 2008. The increase is due primarily to royalty revenues driven by higher product sales of Avastin®, and Lucentis®, which are marketed by Genentech, and sales of Tysabri®, which is marketed by Elan. Royalty revenues are based on first quarter product sales by PDL's licensees and include $18.7 million for Synagis®, which is marketed by MedImmune. Also included in the second quarter revenue estimate is the second and final installment of $12.5 million from Alexion based on the companies' December 2008 settlement and license agreement. When compared with 2008, royalty revenue for foreign sourced sales was negatively impacted by changes in foreign exchange rates; approximately 50 percent of underlying product sales is in currencies other than U.S. dollars.
Most stocks of mine rose signifcantly laterly,but TBTC
drop to $2, even if it earned $0.09 per share last quarter, expecting even better year. do not understand the reason
As expected, OPAI.ob produced strong result with earning over $0.06 per share and even higher operating cash flow in the last quarter (earned $0.2 per share for whole year of 2008). It apperantly has potential to become a 10-bag and even more, considering it is traded merely at $0.11 today at tiny value. Next week it should at least double. But in the un-rational environment, any thing such as mere up 20% or jump 300% could happen.
http://finance.yahoo.com/news/Orient-Paper-Inc-Announces-prnews-14770649.html
TBTC earned $0.09 last quarter and expecting continuing growth in the upcoming year. The stock is traded merely $2.28
http://biz.yahoo.com/e/090320/tbtc.ob10-k.html
OPAI.ob: my first table pounder in the past year
The company earned over $0.05 per share last quarter, with rising earning trend each quarter in the past years. The company is traded at $0.1, with p/e below 1 and healthy balance sheet. Here are the 3 reasons why the company is so undervalued:
1) Paper price drop in the past quarter: the fact is the materials producing paper drop more in the past quarter. Though the company's revenue may slightly be less this quarter than previous one, its earning will continue to grow. More surprisingly, they produced more cash than earning, rarely seen in many growth companies.
2) It is apparent that the company does not have PR, and their press release contains translation errors from time to time, does not present their growing story: This may be the main reason why we can get its share at this cheap.
3) The company tried in the past to get finance to expand faster, but the potential investment bankers wanted to get shares cheap, the company is smart enough to walk away.
There are many more reasons why OPAI may an easy 10-20-bag from here. But I think the above 3 is convincing enough.
Great news for FRX: the key drug will get boost. The sales will rise, along with its earning with great balance sheet.
http://www.cnbc.com//id/28897427?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahoo
CS.to has lots of insiders' buying in the past a few weeks at price far above current trading price:
Jason Howe, CA, VP Finance, bought 25,000 cs shares at $0.85 last Tuesday
Passport Capital, LLC bought over a million shares in the past 6 weeks
Nearly 1 millions option was granted to senior managers at excise price $2.98-$3.57, far above market trading price on the gradning day of November 24
I bought some cs.to today too, but do not understand why there were substantial large amount of shares traded at $0.8 and why its share price did not move higher much considering the copper price and lots of copper companies share price rose lots. I speculate that someone having lots of share want to get out to raise cash, and another guy having lots of money is eager to buy in at this low price.